Modified conditioning regimen with chidamide and high‐dose rituximab for triple‐hit lymphoma

Triple‐hit lymphoma (THL), which is classified into high‐grade B‐cell lymphoma with rearrangements of MYC, BCL2 and BCL6, presents aggressive biological behaviour. High‐dose chemotherapy followed by autologous hematopoietic stem cell transplantation (auto‐HSCT) is considered to be one of the recomme...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Junnan, Zhang, Yizhuo, Ding, Sa, Yasheng, Kalbinur, Li, Yueyang, Yu, Yong, Wang, Yafei, Tian, Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581337/
https://www.ncbi.nlm.nih.gov/pubmed/34698437
http://dx.doi.org/10.1111/jcmm.16999
_version_ 1784596785492131840
author Kang, Junnan
Zhang, Yizhuo
Ding, Sa
Yasheng, Kalbinur
Li, Yueyang
Yu, Yong
Wang, Yafei
Tian, Chen
author_facet Kang, Junnan
Zhang, Yizhuo
Ding, Sa
Yasheng, Kalbinur
Li, Yueyang
Yu, Yong
Wang, Yafei
Tian, Chen
author_sort Kang, Junnan
collection PubMed
description Triple‐hit lymphoma (THL), which is classified into high‐grade B‐cell lymphoma with rearrangements of MYC, BCL2 and BCL6, presents aggressive biological behaviour. High‐dose chemotherapy followed by autologous hematopoietic stem cell transplantation (auto‐HSCT) is considered to be one of the recommended treatment options. Here, we reported 3 THL patients received carmustine, etoposide, cytarabine and cyclophosphamide (BEAC) combined with chidamide and high‐dose rituximab conditioning regimen and found that this conditioning showed good efficacy and tolerance without increase of adverse events.
format Online
Article
Text
id pubmed-8581337
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-85813372021-11-17 Modified conditioning regimen with chidamide and high‐dose rituximab for triple‐hit lymphoma Kang, Junnan Zhang, Yizhuo Ding, Sa Yasheng, Kalbinur Li, Yueyang Yu, Yong Wang, Yafei Tian, Chen J Cell Mol Med Short Communication Triple‐hit lymphoma (THL), which is classified into high‐grade B‐cell lymphoma with rearrangements of MYC, BCL2 and BCL6, presents aggressive biological behaviour. High‐dose chemotherapy followed by autologous hematopoietic stem cell transplantation (auto‐HSCT) is considered to be one of the recommended treatment options. Here, we reported 3 THL patients received carmustine, etoposide, cytarabine and cyclophosphamide (BEAC) combined with chidamide and high‐dose rituximab conditioning regimen and found that this conditioning showed good efficacy and tolerance without increase of adverse events. John Wiley and Sons Inc. 2021-10-25 2021-11 /pmc/articles/PMC8581337/ /pubmed/34698437 http://dx.doi.org/10.1111/jcmm.16999 Text en © 2021 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Communication
Kang, Junnan
Zhang, Yizhuo
Ding, Sa
Yasheng, Kalbinur
Li, Yueyang
Yu, Yong
Wang, Yafei
Tian, Chen
Modified conditioning regimen with chidamide and high‐dose rituximab for triple‐hit lymphoma
title Modified conditioning regimen with chidamide and high‐dose rituximab for triple‐hit lymphoma
title_full Modified conditioning regimen with chidamide and high‐dose rituximab for triple‐hit lymphoma
title_fullStr Modified conditioning regimen with chidamide and high‐dose rituximab for triple‐hit lymphoma
title_full_unstemmed Modified conditioning regimen with chidamide and high‐dose rituximab for triple‐hit lymphoma
title_short Modified conditioning regimen with chidamide and high‐dose rituximab for triple‐hit lymphoma
title_sort modified conditioning regimen with chidamide and high‐dose rituximab for triple‐hit lymphoma
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581337/
https://www.ncbi.nlm.nih.gov/pubmed/34698437
http://dx.doi.org/10.1111/jcmm.16999
work_keys_str_mv AT kangjunnan modifiedconditioningregimenwithchidamideandhighdoserituximabfortriplehitlymphoma
AT zhangyizhuo modifiedconditioningregimenwithchidamideandhighdoserituximabfortriplehitlymphoma
AT dingsa modifiedconditioningregimenwithchidamideandhighdoserituximabfortriplehitlymphoma
AT yashengkalbinur modifiedconditioningregimenwithchidamideandhighdoserituximabfortriplehitlymphoma
AT liyueyang modifiedconditioningregimenwithchidamideandhighdoserituximabfortriplehitlymphoma
AT yuyong modifiedconditioningregimenwithchidamideandhighdoserituximabfortriplehitlymphoma
AT wangyafei modifiedconditioningregimenwithchidamideandhighdoserituximabfortriplehitlymphoma
AT tianchen modifiedconditioningregimenwithchidamideandhighdoserituximabfortriplehitlymphoma

Ejemplares similares